News from janssen pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 29, 2013, 16:37 ET

U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes

Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA™ (canagliflozin) for the...

Mar 14, 2013, 08:30 ET

Doctors Agree Small Lifestyle Changes Can Improve Outcomes of Patients with Type 2 Diabetes, National Survey Finds

 A new, national survey revealed physicians feel type 2 diabetes patients could better manage their disease by appreciating the benefits of...

Feb 05, 2013, 08:00 ET

XARELTO® to be Studied with Factor Xa Inhibitor Antidote

Janssen Pharmaceuticals, Inc. (Janssen) today announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. and Bayer HealthCare...

Nov 30, 2012, 09:47 ET

Janssen erklärt Absicht, Patente von Darunavir in ressourcenknappen Gegenden nicht durchzusetzen

- Die Strategie zielt auf die Unterstützung nachhaltiger Versorgung mit medizinisch vertretbarem, generischem Darunavir in Sub-Sahara-Afrika...

Nov 29, 2012, 16:28 ET

Janssen anuncia su intención de no imponer las patentes para darunavir en entornos con recursos limitados

- La política pretende apoyar el suministro sostenible de darunavir genérico médicamente aceptable en el África subsahariana...

Nov 29, 2012, 14:16 ET

Janssen annonce son intention de ne pas exécuter ses brevets sur le Darunavir dans les régions à ressources limitées

-- Une politique destinée à favoriser l'approvisionnement viable en Darunavir générique médicalement autorisé en...

Nov 29, 2012, 09:00 ET

Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings

 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced their intention not to enforce the patents they own and control...

Nov 12, 2012, 05:45 ET

Nuevos datos de ensayos en fase 2b de simeprevir, de Janssen, en pacientes con hepatitis C y fibrosis hepática avanzada

- Se presentan en la reunión anual de la American Association for the Study of Liver Diseases la eficacia y datos de seguridad de los...

Nov 11, 2012, 07:23 ET
Nov 10, 2012, 09:00 ET
Nov 10, 2012, 08:57 ET

Phase 2 Results Show INCIVO® (telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating Patients Co-infected With Genotype-1 Chronic Hepatitis C Virus and HIV

-  Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV...

Nov 02, 2012, 17:37 ET

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events

Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban), an...

Nov 01, 2012, 07:30 ET

Janssen meldet Zusammenarbeit mit Vertex im Rahmen einer Phase-II-Studie zur Untersuchung der oralen Arzneimittel Simeprevir (TMC435) und VX-135 zur Behandlung von Hepatitis C

Janssen Pharmaceuticals Inc. teilte heute mit, es werde im Rahmen einer nicht ausschließlichen Zusammenarbeit mit Vertex Pharmaceuticals...

Nov 01, 2012, 07:30 ET

Janssen colabora con Vertex en un estudio en fase 2 un régimen completamente oral para la hepatitis C

- Janssen anuncia una colaboración con Vertex en un estudio en fase 2 para la investigación de un régimen completamente oral de...

Nov 01, 2012, 07:30 ET
Nov 01, 2012, 07:30 ET

Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C

 Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated...

Oct 16, 2012, 06:23 ET

Twice-daily INCIVO® (Telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating People Living With Genotype-1 Chronic Hepatitis C Virus

NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for...

Aug 30, 2012, 12:03 ET

Janssen Pharmaceuticals, Inc. announces RISPERDAL® consumer protection settlement with 36 states and the District of Columbia

 Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced a settlement and consent decree today with 36 states and the...

Aug 29, 2012, 08:00 ET

FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)...